Karyopharm Secures $100 Million Financing to Extend Cash Runway and Accelerate Phase 3 SENTRY Myelofibrosis Trial

$100 Million Financing Extends Cash Runway Through Major Data Milestones

Karyopharm Therapeutics (NASDAQ: KPTI) announced a series of comprehensive financing and capital structure transactions totaling $100 million, designed to extend its cash runway into the second quarter of 2026. This provides the company with operational security well beyond the expected top-line readout of its Phase 3 SENTRY trial in myelofibrosis, now targeted for March 2026.

With $46 million in cash on hand before this funding round and anticipated third quarter 2025 revenue between $42 and $44 million (including approximately $32 million in U.S. XPOVIO® sales), this infusion positions Karyopharm to maintain research and development momentum without near-term liquidity constraints.

Strategic Transactions Improve Capital Structure and Lower Near-Term Debt Burden

The newly announced financing includes a blend of new loans, convertible note exchanges, and a private placement. The result is a mix of fresh capital, interest and royalty deferrals, and improved terms with creditors:

Upon closing (expected October 10, 2025), Karyopharm will issue over 7.2 million new shares, pre-funded warrants for nearly 2.9 million shares, and warrants for almost 5.92 million shares—all with an exercise price set at $6.64, reflecting a 15% premium to the Nasdaq minimum price. Existing warrant exercise prices are also being reduced to $6.64 per share, improving potential future conversion activity.

Phase 3 Pipeline on Track: Key Clinical Milestones Approaching

The SENTRY trial—testing selinexor plus ruxolitinib for myelofibrosis—is now fully enrolled. The top-line data, due March 2026, will assess critical outcomes in spleen volume reduction and symptom improvement. The trial targets JAK-inhibitor naïve patients and is structured to potentially establish the first approved combination therapy in this space, aiming to address key limitations of current myelofibrosis treatments such as transfusion dependence and anemia.

In parallel, the EC-042 Phase 3 trial for endometrial cancer continues, with top-line results anticipated by mid-2026. The current funding is expected to support operations until these readouts, removing uncertainty about interim liquidity needs.

Share Count and Capital Structure Implications

Assuming no exercise of pre-funded warrants, new warrants, or conversion of convertible notes, Karyopharm projects an outstanding share count of approximately 15.93 million post-transaction. Investors should note the potential for further dilution if warrants are exercised or notes are converted, given the terms outlined in the new deals.

Key Takeaway: Liquidity Position Supports Clinical Milestones but Raises Dilution Watchpoints

Karyopharm’s decisive financing moves significantly reduce near-term risk, clearing a runway for pivotal clinical results. The combination of debt restructuring, fresh capital, and near-term cash infusions puts the company in a stable position heading into multiple value-creating milestones. However, the size of new share issuances and warrant overhang means existing shareholders will want to monitor further dilution, especially if the upcoming trial data unlocks new upside or capital needs.

As both myelofibrosis and endometrial cancer programs head toward major data events, the strategic shift gives Karyopharm much-needed breathing room. The coming months will show if the pipeline progress justifies the bold capital raise and shareholder dilution—or if the company will need to further optimize its capital structure as it approaches commercial inflection points.

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI